Antiepileptic drugs in the treatment of anxiety disorders: Role in therapy

Drugs

Volumn 64, Issue 19, 2004, Pages 2199-2220

  Van Ameringen, Michael ^a,b   Mancini, Catherine ^a,b   Pipe, Beth ^b   Bennett, Mark ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; AMFEBUTAMONE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; CLONAZEPAM; ETIRACETAM; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; OXCARBAZEPINE; PAROXETINE; PHENYTOIN; PLACEBO; PREGABALIN; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VIGABATRIN;

ABDOMINAL CRAMP; AMNESIA; ANEMIA; ANXIETY DISORDER; ASTHENIA; BRADYCARDIA; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COLITIS; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; EATING DISORDER; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HALLUCINATION; HEADACHE; HUMAN; INDIGESTION; LIBIDO DISORDER; MEMORY DISORDER; MIGRAINE; MONOTHERAPY; MOOD DISORDER; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; OUTCOMES RESEARCH; PANIC; PARESTHESIA; PHOBIA; POSTTRAUMATIC STRESS DISORDER; RASH; RATING SCALE; RESTLESSNESS; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; SUICIDAL BEHAVIOR; SWEATING; THIRST; THOUGHT DISORDER; TRANQUILIZING ACTIVITY; TREMOR; URTICARIA; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTICONVULSANTS; ANXIETY DISORDERS; CANADA; HUMANS; META-ANALYSIS;

EID: 6044274274     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464190-00004     Document Type: Review

References (130)

1. van Steveninck AL, Wallnofer AE, Schoemaker RC, et al. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 1997; 44 (3): 267-75
2. Cowley DS, Roy-Bryne PP, Radant A, et al. Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 1995; 12 (2): 147-57
3. Rapport DJ, Calabrese JR. Tolerance to fluoxetine [letter]. J Clin Psychpharmacol 1993; B (5): 361
4. Pope Jr HG, McElroy SL, Keck Jr PE, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48 (1): 62-8
5. Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987; 48 (3): 89-93
6. Quirk GJ, Gehlert DR. Inhibition of the amygdala: key to pathological states? Ann N Y Acad Sci 2003; 985: 263-72
7. LeDoux JE. The emotional brain. New York: Simon & Schuster, 1996
8. Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry 2003; 64 Suppl. 3: 21-7
9. 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry 2001; 58: 556-61
10. Smith TA. Type A gamma-aminobutryric acid (GABAA) receptors subunits and benzodiazepines binding site sensitivity. Nature 1978; 274: 383-5
11. Rosenberg DR, MacMaster F, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000; 39 (9): 1096-103
12. Mathew SJ, Coplan JD, Gorman JM. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 2001; 158 (10): 1558-67
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994
14. Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine in the treatment of social phobia: a double-blind, placebo-controlled study. Am J Psychiatry 1999; 156: 756-60
15. Stein MB, Liebowitz M, Lydiard RB, et al. Paroxetine in the treatment of generalized social phobia (social anxiety disorder). JAMA 1998; 280: 708-13
16. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 275-81
17. Liebowitz MR, Mangano R. Comparison of venlafaxine extended-release (ER) and paroxetine in the short-term treatment of SAD [poster]. 41st annual meeting of the American College of Neuropsychopharmacology (ACNP); 2002 Dec 8-12; San Juan, Puerto Rico
18. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioural and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991; 48: 938-45
19. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo controlled comparison. Arch Gen Psychiatry 1992; 49 (4): 290-300
20. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch Gen Psychiatry 1998; 55: 1133-41
21. Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. Acta Psychiatr Scand 1995; 92: 251-358
22. Schneier FR, Goetz D, Campeas R, et al. Placebo controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172: 70-7
23. Biton V, Edwards KR, Montouis GD, et al. Topiramate titration and tolerability. Ann Pharmacother 2001; 35: 173-9
24. Van Ameringen M, Mancini C, Pipe B, et al. An open-trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. In press
25. Stein MB, Pollack MH, Mangano R. Long-term treatment of generalized SAD with venlafaxine extended release [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco
26. Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19 (4): 341-8
27. Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001; 132: 1-4
28. Feltner DE, Davidson JRT, Pollack MH, et al. A placebo-controlled, double-blind study of pregabalin treatment of social anxiety disorder: Outcome and predictors of response [abstract]. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico
29. Nardi AE, Mendolwicz M, Versiani FM. Valproic acid in social phobia: an open trial [abstract]. Biol Psychiatry 1997; 42: 118S
30. Kinrys G, Pollack MH, Simon NM, et al. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003; 18: 169-72
31. Fink-Jensen A, Suzdak PD, Swedberg MD, et al. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increased extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992; 220: 197-201
32. Borden LA, Murali Dhar TG, Smith KE, et al. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994; 269 (2): 219-24
33. Papp LA, Ninan PT. Tiagabine for the treatment of social anxiety disorder [abstract]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York
34. Kinrys G, Sudani F, Hsu D, et al. Adjunctive tiagabine for treatment refractory social anxiety disorder [poster]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York
35. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101 (26): 9861-6
36. Simon NM, Worthington JJ, Doyle AC, et al. Levetiracetam for treatment of social anxiety disorder [poster]. Anxiety Disorders Association of America's 23rd National Conference; 2004 Mar 16-20; Miami
37. Ballenger JA, Davidson JRT, Lecrubier Y, et al. Consensus statement on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 2000; 61 Suppl. 5: 60-6
38. Connor KM, Sutherland SM, Tupler LA, et al. Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. Br J Psychiatry 1999; 175: 17-22
39. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55: 517-22
40. Davidson JR, Rothbaum BO, van der Kolk BA, et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001 May; 58 (5): 485-92
41. Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible dosage trial. J Clin Psychiatry 2001; 62 (11): 860-8
42. Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158 (12): 1982-8
43. Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991; 179 (6): 366-70
44. Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline or placebo. Arch Gen Psychiatry 1990; 47 (3): 259-66
45. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60 (2): 79-88
46. Hertzberg MA, Butterfield MI, Fledman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1997; 45 (9): 1226-9
47. Berlant J, Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002; 63 (1): 15-20
48. Chengappa KN, Rathore D, Levine J, et al. Topiramate as add- on treatment for patients with bipolar mania. Bipolar Disord 2001; 3 (5): 215-32
49. Brannon N, Labbate L, Huber M. Gabapentin treatment for posttraumatic stress disorder [letter]. Can J Psychiatry 2000; 45: 84
50. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13 (3): 141-6
51. Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder [letter]. Am J Psychiatry 1991; 148 (8): 1086-7
52. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; 52 (9): 361-4
53. Petty F, Davis LL, Nugent AL, et al. Valproate therapy for chronic, combat-induced posttraumatic stress disorder [letter]. J Clin Psychopharmol 2002; 22 (1); 100-2
54. Otte C, Wiedemann K, Yassouridis A, et al. Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study [letter]. J Clin Psychopharmacol 2004; 24 (1): 106-8
55. Lara ME. Tiagabine for augmentation of antidepressant treatment of post-traumatic stress disorder [poster]. 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21-24; Austin
56. Berigan T. Treatment of posttraumatic stress disorder with tiagabine [letter]. Can J Psychiatry 2002; 47 (8): 788
57. Davidson J, Weisler R, Connor K, et al. Tiagabine for posttraumatic stress disorder: a placebo-controlled trial [poster). 24th Annual Conference of the Anxiety Disorders Association of America; 2004 Mar 11-14; Miami
58. Lipper S, Davidson JRT, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; 27 (12): 849-54
59. Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry 1988; 23: 642-4
60. Looff D, Grimely P, Kuller F, et al. Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry 1995; 34 (6): 703-4
61. Macleod AD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol 1996; 16 (2): 190-1
62. Berigan T. Oxcarbazepine treatment of posttraumatic stress disorder [letter]. Can J Psychiatry 2002; 47 (10): 973-4
63. Andersch S, Rosenberg NK, Kullingsjo H, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand 1991; 365: 18-27
64. Modgh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251-61
65. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37 (1): 51-9
66. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52: 69-76
67. Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed-dose study of alprazolam 2mg, alprazolam 6mg, and placebo in panic disorder. J Clin Psychopharmocol 1992; 12: 96-103
68. Wade AG, Lepola U, Koponon HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549-53
69. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36-42
70. Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998; 173: 54-60
71. Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001; 103 (1): 1-14
72. Michelson D, Allgulander C, Dantendorfer K, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomized, placebo-controlled trial. Br J Psychiatry 2001; 179: 514-8
73. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders [letter]. Am J Psychiatry 1998; 155 (7): 992-3
74. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20 (4): 467-71
75. Brady KT, Sonne S, Lydiard RB. Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients [letter]. J Clin Psychopharmol 1994; 14 (1): 81-2
76. Roberts JM, Malcolm R, Santos AB. Treatment of panic disorder and comorbid substance abuse with divalproex sodium [letter]. Am J Psychiatry 1994; 151 (10): 1521
77. McElroy S, Keck PE, Lawerence JM. Treatment of panic disorder and benzodiazepine withdrawal with valproate [letter]. J Neuropyschiatry Clin Neurosci 1991; 3 (2): 232-3
78. Marazziti D, Cassano G. Valproic acid for panic disorder associated with multiple sclerosis [letter]. Am J Psychiatry 1996; 153 (6): 842-3
79. Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992; 17 (2): 78-80
80. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990; 35: 248-50
81. Woodman CL, Noyles R. Panic disorder: treatment with valproate. J Clin Psychiatry 1994; 55 (4): 134-6
82. Keck PE, Talyor VE, Tugrul KC, et al. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33: 542-6
83. Baetz M, Bowen R. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998; 43 (1): 73-7
84. Lum M, Fontaine R, Elie R, et al. Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study [abstract]. Biol Psychiatry 1990; 27: 164A
85. Gruener D. Tiagabine as an augmenting agent for the treatment of anxiety [poster]. 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21-24; Austin
86. Zwanzger P, Baghai TC, Schule C, et al. Tiagabine improves panic and agoraphobia in panic disorder patients [letter]. J Clin Psychiatry 2001; 62 (8): 656-7
87. Zwanger P, Eser D, Padberg F, et al. Effects of tiagabine treatment on cholecystokin-tetrapeptide (CCK-4) induced anxiety in healthy volunteers [abstact P.4.W.064]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S215
88. Lawlor BA. Carbamazepine, alprazolam withdrawal, and panic disorder. Am J Psychiatry 1987; 144 (2): 265-6
89. Tondo L, Burrai C, Scamonatti L, et al. Carbamazepine in panic disorder. Am J Psychiatry 1989; 146: 558-9
90. Uhde TW, Stein MB, Post RM. Lack of efficacy of Carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988; 145: 1104-9
91. McNamara ME, Fogel BS. Anticonvulsant-responsive panic attacks with temporal lobe EEG abnormalities. J Neuropsychiatry Clin Neurosci 1990; 2: 193-6
92. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002; 63 Suppl. 14: 9-16
93. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50 (11): 884-95
94. Strand M, Hetta J, Rosen A, et al. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990; 51 Suppl.: 40-5
95. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62 (5): 350-7
96. Rynn MA, Siwueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158 (12): 2008-14
97. Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry 1999; 60 Suppl. 1: 2-19
98. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157 (6): 968-74
99. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160 (3): 533-40
100. Lydiard B, Bielski RJ, Zornberg GL, et al. Efficacy of pregabalin in treating psychic and somatic symptoms in generalized anxiety disorder (GAD) [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco
101. Montgomery SA, Rickels K, Belski RJ, et al. Pregabalin in generalized anxiety disorder: speed of onset [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco
102. Pollack MH, Zimbroff DL, Tobia K, et al. Pregabalin in generalized anxiety disorder: analyses of subsyndromic depression [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco
103. Papp LA, Ray S. Tiagabine treatment of generalized anxiety disorder [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco
104. Rosenthal MH, Dolnak D. Tiagabine for the treatment of generalized anxiety disorder [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco
105. Van Ameringen M, Pollack MH, Roy-Byrne. A randomized, double-blind, placebo-controlled study of tiagabine in patients with generalized anxiety disorder [poster]. 24th Collegium Internationale Neuro-Psychopharmacologicium (CINP) Congress; 2004 Jun 20-24; Paris
106. Pollack M. Levetiractam (Keppra) for anxiety. Curbside Consultant 2002; 1 (4): 4
107. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder: OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169 (4): 468-74
108. Tllefson GD, Rampey Jr AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51 (7): 559-67
109. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20mg, 40mg, and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16 (2): 75-86
110. Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996; 11 (1): 21-9
111. Kronig MH, Apter J, Asnis G, et al. Placebo-controlled, multicenter study of sertraline treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1999; 19 (2): 172-6
112. Clomipramine Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 730-8
113. Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992; 161: 665-70
114. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302-8
115. Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000; 10 (3): 165-9
116. McDougle CJ, Epperson CN, Peolton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794-801
117. Cora-Locatelli G, Greenberg BD, Martin J, et al. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. J Clin Psychiatry 1998; 59 (9): 480-1
118. Cora-Locatelli G, Greenberg BD, Martin J, et al. Rebound psychiatric and physical symptoms after gabapentin discontinuation [letter]. J Clin Psychiatry 1998; 59 (3): 131
119. Deltito JA. Valproate pretreatment for the difficult-to-treat patient with OCD [letter]. J Clin Psychiatry 1994; 55 (11): 500
120. Cora-Locatelli G, Greenberg BD, Martin JD, et al. Valproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry 1998; 59: 82
121. Iwata Y, Kotani Y, Hoshino R, et al. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry 2000; 61 (7): 528-9
122. Jenike MA, Brotman AW. The EEG in obsessive-compulsive disorder. J Clin Psychiatry 1984; 45: 122-4
123. Joffe RT, Swinson RP. Carbamazepine in obsessive-compulsive disorder. Biol Psychiatry 1987; 22 (9): 1169-71
124. Van Ameringen M, Mancini C, Pipe B, et al. Adjunctive topiramate in treatment resistant obsessive compulsive disorder [poster]. 157th Annual Meeting of the American Psychiatric Association (APA); 2004 May 1-6; New York
125. Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 2000; 34: 527-8
126. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60 (4): 392-400
127. Crane DL. The selective GABA reuptake inhibitor tiagabine for the treatment of anxiety [poster]. 22nd National Conference of the Anxiety Disorders Association of America; 2002 Mar 21-24; Austin
128. Schwartz TL, Ashar N, Husain J, et al. Open-label study of tiagabine augmentation therapy for anxiety disorders [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco
129. Taylor F. Tiagabine for the treatment of posttraumatic stress disorder [poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco
130. Kennedy SH, Lam RW, Cohen N, et al. Clinical guidelines for the treatment of depressive disorders: IV. Medication and other biological treatments. Can J Psychiatry 2001; 46 Suppl. 1: 38S-58S